Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

• Eric J. Tarcha,

  Roles Conceptualization, Investigation, Supervision, Writing – review & editing

  Affiliation Kineta Inc., Seattle, WA, United States of America

  ⨯
• Chelsea M. Olsen ,

  Roles Data curation, Project administration, Writing – original draft, Writing – review & editing

  * E-mail: colsen@kpitherapeutics.com

  Current address: KPI Therapeutics Inc., Seattle, WA, United States of America

  Affiliation Kineta Inc., Seattle, WA, United States of America

  http://orcid.org/0000-0001-5177-1882

  ⨯
• Peter Probst,

  Roles Data curation, Writing – review & editing

  Affiliation Kineta Inc., Seattle, WA, United States of America

  ⨯
• David Peckham,

  Roles Data curation, Formal analysis, Methodology, Writing – review & editing

  Affiliation Kineta Inc., Seattle, WA, United States of America

  ⨯
• Ernesto J. Muñoz-Elías,

  Roles Conceptualization

  Current address: Department of Immunodermatology, Janssen Research & Development, Johnson & Johnson, San Diego, CA, United States of America

  Affiliation Kineta Inc., Seattle, WA, United States of America

  ⨯
• James G. Kruger,

  Roles Data curation, Formal analysis, Writing – review & editing

  Affiliation Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, United States of America

  ⨯
• Shawn P. Iadonato

  Roles Conceptualization, Data curation, Formal analysis, Investigation, Supervision, Validation

  Affiliation Kineta Inc., Seattle, WA, United States of America

  ⨯